论文部分内容阅读
目的：观察和分析１５例Ｂｕｒｋｉｔ′ｓ淋巴瘤的临床特征和治疗转归。方法：男１２例，女３例，以儿童为主，≤１５岁１１例（７３．３％），＞１５岁４例（２６．７％），中位年龄１２岁。以晚期为主，Ⅲ＋Ⅳ期１１例（７３．３％）。首发部位多见于颌面部及外周淋巴结。有Ｂ症状者５例（３３．３％），有骨髓侵犯者４例（２６．７％），中枢神经系统侵犯者１例，有结外多器官侵犯者５例（３３．３％）。１５例均采用了联合化疗，以ＣＯＭ或ＣＯＭＰ及ＢＡＣＯＰ方案为主。结果：ＣＲ５例，ＰＲ４例，总缓解率６０％，中位缓解期８个月。全组中位生存期７个月，２年生存率４２．５％，５年生存率２３．１％。早期（Ⅰ＋Ⅱ期）及化疗有效者（ＣＲ＋ＰＲ）较晚期（Ⅲ＋Ⅳ期）、化疗无效者（ＳＤ＋ＰＤ）中位生存期明显延长。有Ｂ症状、骨髓侵犯、中枢神经系统侵犯及结外多器官侵犯者中位生存期明显缩短。结论：我国Ｂｕｒｋｉｔ′ｓ淋巴瘤晚期、多器官侵犯者多，较非洲儿童预后差，但经联合化疗尤大剂量化疗能取得较好的疗效，能适当延长生存期。
Objective: To observe and analyze the clinical features and treatment outcomes of 15 cases of Burkit’s lymphoma. Methods: 12 males and 3 females, mainly children, 11 cases (73.3%) ≤ 15 years old, >15 years old (26.7%), median age 12 years old. The advanced stage was mainly in 11 cases (73.3%) in stage III+IV. The first site is more common in the maxillofacial and peripheral lymph nodes. There were 5 patients with B symptoms (33.3%), 4 patients with bone marrow involvement (26.7%), 1 patient with central nervous system violations, and 5 patients (33.3%) with extranodal involvement. All 15 patients were treated with combination chemotherapy and COM or COMP and BACOP were the main options. Results: CR5 cases, PR4 cases, total remission rate 60%, median remission period of 8 months. The median survival time of the whole group was 7 months, the 2-year survival rate was 42.5%, and the 5-year survival rate was 23.1%. The median survival time was significantly longer in early (I+II) and chemotherapy (CR+PR) than late (III+IV) and chemotherapy-ineffective (SD+PD) patients. The median survival time was significantly shorter in patients with B symptoms, bone marrow invasion, central nervous system violations, and extranodal involvement. Conclusion: There are many patients with advanced Burkit′s lymphoma and multiple organ invasion in our country. The prognosis is poorer than that of African children. However, combined chemotherapy, especially high-dose chemotherapy, can achieve better efficacy and can prolong survival time.